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ORIGINAL ARTICLE
Synthetic compounds from an in house library as inhibitors of falcipain-2
from Plasmodium falciparum
Jean Borges Bertoldo1, Louise Domeneghini Chiaradia-Delatorre1,2, Alessandra Mascarello2, Paulo César Leal1,
Marlon Norberto Sechini Cordeiro2, Ricardo José Nunes2, Emir Salas Sarduy3, Philip Jon Rosenthal4, and
Hernán Terenzi1
1Centro de Biologia Molecular Estrutural (CEBIME) and 2Laboratório Estrutura e Atividade (LEAT), Universidade Federal de Santa Catarina, Campus
Trindade, Florianópolis – SC, Brasil, 3Facultad de Biologı́a, Centro de Estudio de Proteı́nas, Universidad de la Habana, Habana, Cuba, and
4Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA
Abstract
Falcipain-2 (FP-2) is a key cysteine protease from the malaria parasite Plasmodium falciparum.
Many previous studies have identified FP-2 inhibitors; however, none has yet met the criteria
for an antimalarial drug candidate. In this work, we assayed an in-house library of non-peptidic
organic compounds, including (E)-chalcones, (E)-N’-benzylidene-benzohydrazides and alkyl-
esters of gallic acid, and assessed the activity toward FP-2 and their mechanisms of
inhibition. The (E)-chalcones 48, 54 and 66 showed the lowest IC50 values (8.5 ± 0.8 mM,
9.5 ± 0.2mM and 4.9 ± 1.3 mM, respectively). The best inhibitor (compound 66) demonstrated
non-competitive inhibition, and using mass spectrometry and fluorescence spectroscopy
assays, we suggest a potential allosteric site for the interaction of this compound, located
between the catalytic site and the hemoglobin binding arm in FP-2. We combined structural
biology tools and mass spectrometry to characterize the inhibition mechanisms of novel
compounds targeting FP-2.
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Introduction
Malaria, a disease caused by Plasmodium falciparum, is one of
the most serious infectious disease in the world, leading to about
627 000 deaths in 20121. A key factor contributing to the inability
to control this disease is the resistance to nearly all available
antimalarial drugs1.
Erythrocytic P. falciparum parasites take up hemoglobin from
erythrocyte cytosol and transport it to an acidic food vacuole,
where it is hydrolyzed, and used as a source of amino acids2.
Among the P. falciparum proteases that hydrolyze hemoglobin is
the cysteine-protease falcipain-2 (FP-2)3, which was shown to be
responsible for 93% of the total hemoglobin proteolysis encoun-
tered in soluble trophozoite extracts3,4, being a key enzyme for the
successful establishment of a P. falciparum infection5. Another
P. falciparum cysteine protease, falcipain-3, is also a key
hemoglobinase that is biochemically similar to FP-2, but it is
active later than FP-2 along the life cycle6.
Several studies have focused on FP-2 as a promising target for
antimalarial chemotherapy7,8, and several classes of organic
compounds have been identified as FP-2 inhibitors, including
peptides, peptidomimetics, isoquinolines, thiosemicarbazones and
chalcones9, with both reversible and irreversible mechanisms of
action. Despite the potency of some described inhibitors such as
peptidyl vinyl sulfones10 and pyrimidine nitriles11, no compound
has progressed through the drug discovery pipeline to the
candidate stage. Nonetheless, FP-2 remains a promising target
for antimalarial chemotherapy.
In this context, chalcones, benzohydrazides and alkyl-esters of
gallic acid are of particular interest since these classes of
compounds present a variety of biological activities. Chalcones
are intermediate compounds in flavonoid biosynthesis presenting
a benzalacetophenone fundamental core12, and benzohydrazides
are compounds structurally related to them having the propanone
group replaced by a hydrazide group. The alkyl esters of gallic
acid are derived from the natural triphenol flavonoid gallic acid
and are widely used in food and pharmaceutical industries as
antioxidants13. Several reports have documented the properties of
natural or synthesized chalcones, benzohydrazides and alkyl-
esters of gallic acid, which include antitumoral, antiinflammatory,
antimicrobial and antiviral, among other biological activities14–19.
Chalcones and benzohydrazides had already been studied as
antimalarial compounds14–16 and as FP-2 inhibitors9.
In this work, we assayed an in-house library of non-peptidic
organic compounds, including 82 (E)-chalcones, 17 (E)-N0-
benzylidene-benzohydrazides and 11 alkyl-esters of gallic acid
(Figure 1), and assessed their activity toward FP-2 inhibition and
their mechanism of action.
Address for correspondence: Prof. Dr. Hernán Terenzi, Centro de
Biologia Molecular Estrutural, Universidade Federal de Santa Catarina,
Campus Trindade, CEP: 88040–900, Florianópolis – SC, Brasil. Tel: +55
48 3721 6426. Fax: +55 48 3721 9672. E-mail: hterenzi@ccb.ufsc.br
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Materials and methods
Synthesis and purification of the compounds
The 110 assayed synthetic compounds (Table S1, Supplementary
information), were prepared as described in our previous
reports19–29. Reagents were obtained from Sigma-Aldrich
(St. Louis, MO) and solvents from Vetec (Duque de Caxias, RJ,
Brazil).
The (E)-chalcones 1–82 were prepared by aldol condensation
using methanol as solvent under basic conditions (KOH 50% w/v)
at room temperature for 24 h. Distilled water and 10% hydro-
chloric acid were added to the reaction for total precipitation of
the compounds, which were then obtained by vacuum filtration
and later recrystallized in dichloromethane and hexane20–29.
The (E)-N0-benzylidene-benzohydrazides 83–99 were
synthesized by condensation of the benzohydrazide (2 mmol)
or 3,4,5-trimethoxy-benzohydrazide (2 mmol), with the appro-
priate aldehyde (2 mmol) in methanol (15 mL) and refluxed for
2 h. After cooling, the crude product was collected by
filtration, washed and recrystallized from hot ethanol to give
white solids20–29.
To obtain the alkyl-esters of gallic acid 100–110, gallic acid
(5 mmol) and the corresponding alcohol (15 mmol) were mixed.
The mixture was dissolved in toluene (70 mL) and sulfuric acid
concentration (0.4 mL), heated for 8–12 h in reflux using Dean-
Stark, and the solvent was removed under reduced pressure.
Alternatively, the mixture was dissolved in dioxane (10 mL) and
p-toluenesulfonic acid (0.3 mL), and heated for 2–4 h in bath oil
under vacuum. All products were purified by column
chromatography19.
The purity of the compounds was confirmed by melting point
measurement (with a MGAPF-301 apparatus), infrared spectros-
copy (in an Abb Bomen FTLA 2000 spectrometer on KBr disks;
Zurich, Switzerland) and 1H and 13C nuclear magnetic resonance
spectroscopy (on a Varian Oxford AS-400 400 MHz instrument;
Agilent Technologies, Santa Clara, CA), as well as elementary
analysis (carried out using a CHNS EA 1110). The chemical
characterization of the three more active compounds is shown.
48 – (2E)-1-(30-nitrophenyl)-3-(1,3-benzodioxol-5-yl)-2-
propen-1-one. Brown solid, m.p. 144–146 C; 1H NMR
(CDCl3) d 6.05 (s, 2H, –OCH2O–), 6.86 (d, 1H, J¼ 8.0 Hz,
H5), 7.15 (d, 1H, J¼ 8.0 Hz, H6), 7.19 (s, 1H, H2), 7.36 (d, 1H,
J¼ 15.2 Hz, Ha), 7.70 (m, 1H, H50), 7.81 (d, 1H, J¼ 15.2 Hz,
Hb), 8.33 (d, 1H, J¼ 8.0 Hz, H60), 8.43 (d, 1H, J¼ 8.0 Hz, H40),
8.81 (s, 1H, H20). 13C NMR (CDCl3) d 102.1 (–OCH2O–), 107.0
(C2), 109.0 (C5), 118.8 (C6), 123.4 (Ca), 126.2 (C60), 127.2 (C1),
129.0 (C40), 130.1 (C50), 134.3 (C20), 139.9 (C10), 146.9 (Cb),
148.6 (C30), 148.8-150.8 (C3, C4), 188.1 (C¼O). IR max/cm–1
1661, 1211 (C¼O), 1588 (C¼C), 1248, 1036 (C–O), 1527, 1347,
850 (N¼O), 3040, 2900, 1609, 1503, 1489, 1446, 1102, 927, 808,
700 (Ar) (KBr). Anal. Calcd for C16H11NO5: C 64.65; H 3.73;
N 4.71; found: C 64.70; H 3.80; N 4.99. Yield¼ 40%.
54 – (2E)-1-(30-nitrophenyl)-3-(2,4,5-trimethoxyphenyl)prop-
2-en-1-one. Dark yellow solid, m.p. 161–162 C; 1H NMR
(400 MHz, DMSO-d6) d 3.83 (s, 3H, o-OCH3), 3.89 (s, 3H,
m-OCH3), 3.92 (s, 3H, p-OCH3), 6.77 (s, 1H, H3), 7.58 (s, 1H,
H6), 7.84 (d, 1H, J¼ 16.0 Hz, Ha), 7.88 (t, 1H, J¼ 8.0 Hz, H50),
8.16 (d, 1H, J¼ 16.0 Hz, Hb), 8.49 (dd, 1H, J¼ 8.0/1.0 Hz, H60),
8.61 (dd, 1H, J¼ 8.0/1.0 Hz, H40), 8.77 (m, 1H, H20); 13C NMR
(100 MHz, DMSO-d6) d 55.8 (o-OCH3), 56.3 (m,p-OCH3), 97.3
(C3), 111.0 (C1), 113.9 (C6), 117.7 (C20), 122.5 (Ca), 126.9
(C40), 130.4 (C50), 134.5 (C60), 139.2 (C10), 139.9 (Cb), 143.0
(C2), 148.1 (C30), 153.4 (C5), 154.7 (C4), 187.1 (C¼O). Anal.
Calcd for C18H17NO6: C 62.97, H 4.99, N 4.08. Found: C 63.15,
H 5.03, N 4.06. Yield¼ 83%.
66 – (2E)-1-(20,40,50-trimethoxyphenyl)-3-[5-(2-chloro-5-tri-
fluoromethyl-phenyl)-furan-2-yl]-2-propen-1-one. Gold
yellow solid, m.p. 134–136 C; 1H NMR (CDCl3) d 3.91 (s, 3H,
o-OCH3), 3.96 (s, 3H, m-OCH3), 3.99 (s, 3H, p-OCH3), 6.57 (s,
1H, H30), 6.78 (d, 1H, J¼ 4.0 Hz, H5), 7.33 (d, 1H, J¼ 4.0 Hz,
H4), 7.46 (s, 1H, H60), 7.47 (dd, 1H, J¼ 8.0/1.0 Hz, H300), 7.54 (d,
1H, J¼ 16.0 Hz, Ha), 7.59 (d, 1H, J¼ 8.0 Hz, H400), 7.81 (d, 1H,
J¼ 16.0 Hz, Hb), 8.25 (s, 1H, H600). 13C NMR (CDCl3) d 56.2 (o-
OCH3), 56.3 (m- and p-OCH3), 96.7 (C3
0), 113.2 (C60), 114.8
(C5), 117.0 (C4), 119.9 (C10), 123.7 (CF3), 124.8 (C4
00), 124.9
(C600), 126.1 (Ca), 127.4 (C300, C500), 129.2 (C200), 131.6 (Cb),
133.8 (C100), 143.4 (C50), 149.9 (C1), 152.2 (C3), 154.0 (C20),
155.3 (C40), 188.5 (C¼O). IR max/cm–1 1649, 1224 (C¼O), 1585
(C¼C), 1141 (C–Cl), 1265, 1027 (C–O), 1164 (C–F), 2954, 2844,
1610, 1515, 1466, 1402, 1333, 1110, 986, 899, 791, 678 (Ar)
(KBr). Anal. Calcd for C23H18ClF3O5: C 59.17, H 3.89. Found: C
58.63, H 3.21. Yield¼ 92%.
Plasmid for expression of FP-2
Plasmid pTrcHis2A-35proFP2 containing the 875 bp FP-2 gene is
described in the original report for FP-2 expression3, the construct
was designed to include the catalytic domain of FP-2, 35 residues
from N-terminal pro-domain and a 6xhis-tag30.
Expression, purification and refolding of FP-2
A BL21-DE3 Escherichia coli colony harboring the pTrcHis2A-
35proFP2 plasmid was transferred to a 10 mL Luria-Bertani (LB)
medium tube containing 100 mg/mL ampicillin and grown
overnight at 37 C. Thereafter, 10 mL medium were transferred
to a 250-mL flask containing LB medium with the same antibiotic
concentration and grown at 37 C until OD600¼ 0.8 was reached.
Isopropyl b-D-thiogalactoside 1 mM was used to induce bacterial
expression, and maximal expression was achieved after four hours
at 37 C30. Cells were harvested by centrifugation (5000 g, 4 C,
20 min), resuspended in cold buffer (100 mM Tris-HCl, EDTA
10 mM, pH 7.4) and disrupted by sonication (12 cycles, 10 s, 10 s
rest). The homogenate was then centrifuged at 12 000 g, 4 C
for 30 min. The pellet was washed once with cold buffer A (2.5 M
urea, 20 mM Tris-HCl, 2.5% Triton X-100, pH 8.0), centrifuged at
17 000 g, 4 C for 30 min and solubilized in buffer B (6 M
guanidine HCl, 20 mM Tris-HCl, 250 mM NaCl, 20 mM
Figure 1. Generic chemical structure of the three classes of compounds
assayed in this work: (E)-chalcones 1–82, (E)-N0-benzylidene-benzohy-
drazides 83–99, and alkyl-esters of gallic acid 100–110.
300 J. B. Bertoldo et al. J Enzyme Inhib Med Chem, 2015; 30(2): 299–307
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imidazole, pH 8.0) for 60 min. The suspension was centrifuged at
27 000 g 4 C for 30 min to remove all insoluble content. The
supernatant was loaded on a Ni2+-NTA resin (Qiagen, Venlo,
Netherlands) previously equilibrated with buffer (8 M urea,
30 mM imidazole, 20 mM Tris-HCl, pH 8.0). The resin was
washed sequentially with the same buffer, containing 30, 60 and
100 mM imidazole. Finally, FP-2 was eluted with imidazole 1 M,
and reduced with dithiothreitol (DTT) 10 mM at 37 C for 45 min.
Refolding was carried out in a buffer (100 mM Tris-HCl, 1 mM
EDTA, 250 mM L-arginine, 30% glycerol, 1 mM reduced
glutathione (GSH), 1 mM oxidized glutathione (GSSG), pH 9.0)
with a 100-fold dilution of reduced FP-2 into 200 mL of the ice-
cold buffer. Complete processing of the active form of FP-2 was
achieved as previously described31.
Enzymatic assay for FP-2 inhibition
Stock solutions of the 110 synthesized compounds were prepared at
10 mM in 100% DMSO. Fluorimetric assays were performed in a
buffer (100 mM NaOAc, 10 mM DTT, pH 5.5) using Z-FR-AMC
(7-amino-4-methylcoumarin, N-CBZ-L-phenylalanyl-L-arginine
amide) as a substrate. FP-2 (70 nM) was incubated for five minutes
at room temperature with 50 mM of each of the 110 compounds
before substrate addition. The AMC release after hydrolysis was
monitored for one minute at room temperature in a fluorimeter
(Cary Eclipse, Agilent, Agilent Technologies, Santa Clara, CA)
with excitation set to 355 nm and emission at 460 nm. All scans
were corrected from the corresponding blanks, and controls
(FP-2 + DMSO 2%, Z-FR-AMC + DMSO 2% and FP-2 + Z-FR-
AMC + DMSO 2%). Compounds capable of inhibiting at least 85%
of the FP-2 activity in the initial screening were selected to
determine IC50 values. The experiments were done four times, and
IC50 values were derived from plots of activity over at least six
compound concentrations.
Kinetic assays
Compounds with IC50 values below 10 mM were selected to
discriminate the mechanism of inhibition. Ki values were obtained
from replots of KMapp or Vi over inhibitor concentration. At least
three different concentrations of the selected inhibitors and seven
concentrations of the substrate (1–64mM) were used in the assays,
which were repeated at least five times.
Mass spectrometry
Inhibitors with IC50 values below 10 mM were selected for mass
spectrometry analyses. The experiments were done following
the previously published methodology32 with minor changes. In
a final reaction volume of 10 mL, approximately 1mM FP-2 was
incubated in the presence of the selected inhibitors (100 or
300mM) in 100 mM NaOAc, 10 mM DTT, pH 5.5 for 5 min at
room temperature (final DMSO concentration 2%). FP-2 was
also incubated in the presence of the substrate and used as a
control. Finally, 40 mL of 25 mM NH4HCO3, pH 8.0 were
added to the reaction, followed by trypsin (10 ng/mL with a
protease:protein ratio of 0.5:1.0 (w/w)) (Promega, Madison,
WI). The reactions containing FP-2, selected inhibitors and
trypsin were incubated at 37 C for three hours with gentle
stirring. After digestion, about 1mL of each reaction was mixed
with 9mL of the matrix a-cyano-4-hydroxycinnamic acid (5 mg/
mL) dissolved in 50% acetonitrile and 3% trifluoracetic acid,
then, 1mL of this mixture was spotted in triplicate in a MALDI
MTP 384 target polished steel plate (Bruker Daltonics, Bremen,
Germany). MS analysis was performed on a matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF)/TOF spectrometer model Autoflex III (Bruker
Daltonics) equipped with a 337 nm nitrogen laser (Smartbeam
200 Hz) using an extracting voltage of 20 kV, ion gate 400 m/z,
4000 laser shots over a mass range from 800 to 4000 m/z. All
experiments were done at least three times in the automated
mode, and the spectra were processed using FlexAnalysis 3.3
sofware (Bruker Daltonics).
Fluorescence analyses
FP-2 (1 mM) was incubated in the presence of 100mM of the
selected inhibitors for 5 min in 100 mM NaOAc, 10 mM DTT, pH
5.5 at room temperature, in a quartz cuvette. The measurements
were obtained in a JASCO J815 Spectropolarimeter (JASCO,
Easton, MD) equipped with a fluorescence detection unit (FMO-
427). Fluorescence excitation was set to 295 nm in order to excite
only tryptophans, and the emission was scanned over the range
from 320 to 500 nm. The assays were done in triplicate.
Molecular modeling
FP-2 models were constructed with the PyMOL Software version
1.5 (Delano Scientific LLC, Philadelphia, PA) using the PDB file
2GHU33.
Results and discussion
Inhibition of FP-2 activity
An in-house library of 110 compounds, including 82 (E)-
chalcones, 17 (E)-N0-benzylidene-benzohydrazides and 11 alkyl-
esters of gallic acid, were screened against recombinant FP-2. In
initial screening, 17 compounds inhibited FP-2 activity 85%,
Table 1. IC50 values of compounds active against recombinant falcipain-2.
Compound Chemical structure IC50 value (mM)
2 O
O2N
12.0 ± 2.1
10
O2N
O 420
23 O Cl
Cl
420
24 O
NO2
19.1 ± 1.5
34 O
O
O
O
CH3
11.2 ± 0.3
39 O
OCH3
OCH3
OCH3
O
O
420
43 O
O
O
NO2
14.8 ± 1.4
(continued )
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including 14 (E)-chalcones (2, 10, 23, 24, 34, 39, 43, 48, 54, 57,
66, 72, 76 and 79) and three alkyl-esters of gallic acid (104, 105
and 106) (Table S1, Supplementary information). These 17
compounds were selected to determine the IC50 values (Table 1).
The three alkyl-esters of gallic acid (104, 105 and 106) and
(E)-chalcones (10, 23, 39, 57, 72, 76 and 79) slightly inhibited
FP-2, with IC50420 mM. Compounds 2, 24, 34 and 43 had modest
activity (IC50¼ 10–20mM), and interestingly the (E)-chalcones
48, 54 and 66 were the most active compounds, with IC50 values
below 10 mM.
Among the (E)-chalcones, inhibitor 66 (IC50¼ 4.9 ± 1.3 mM)
has a 2,4,5-trimethoxyphenyl group at A-ring position, and a 2-(2-
chloro-5-(trifluoromethyl)phenyl)furan group as its B-ring.
Switching the A-ring to a 2,5-dimethoxyphenyl group (compound
81) or a 3,4-methylenedioxyphenyl group (compound 44) led
to a decrease in inhibitory activity (data not shown). Replacing
the B-ring of compound 66 with a 3-chlorophenyl ring (com-
pound 57, IC50420 mM) also decreased inhibitory activity at
least 4-fold.
Both the (E)-chalcones 48 (IC50¼ 8.5 ± 0.8mM) and 54
(IC50¼ 9.5 ± 0.2 mM) showed similar inhibitory activity, and
contain a 3-nitrophenyl group as the A-ring, and a 3,4-
methylenedioxyphenyl or 2,4,5-trimethoxyphenyl group as the
B-ring. The inhibitory activity was slightly reduced when the
B-ring was changed to the 1-naphthyl group (compound 2,
Table 1. Continued
Compound Chemical structure IC50 value (mM)
48 O
O
OO2N
8.5 ± 0.8
54 O
OCH3
O2N
OCH3
OCH3 9.5 ± 0.2
57
OCH3
H3CO
OCH3O
Cl
420
66
H3CO
OCH3
CF3
OCH3
O
O
Cl 4.9 ± 1.3
72 O
O
OCH3
H3CO
H3CO
CH3
420
76
OCH3
H3CO
H3CO
O
S
420
79 O
Cl
OCH3H3CO
OCH3
Cl
420
104
O
O
HO
HO
OH
420
105
O
O
HO
HO
OH
420
106
O
O
HO
HO
OH
420
Figure 2. Lineweaver–Burk plots of the kinetic behavior of inhibitors 48,
54 and 66. The plots represent an average of at least five different
experiments.
302 J. B. Bertoldo et al. J Enzyme Inhib Med Chem, 2015; 30(2): 299–307
D
ow
nl
oa
de
d 
by
 [
E
m
ir
 S
al
as
-S
ar
du
y]
 a
t 0
7:
47
 0
6 
A
ug
us
t 2
01
5 
IC50¼ 12.0 ± 2.1mM) and reduced 2-fold when the B-ring was the
2-naphthyl group (compound 10, IC50420 mM). When the rings
of compound 48 (IC50¼ 8.5 ± 0.8mM) were inverted, forming
compound 43 (IC50¼ 14.8 ± 1.4 mM) with a 3-nitrophenyl group
as B-ring, the inhibitory activity was reduced almost 50%.
Similarly, the inversion of the rings of compound 54
(IC50¼ 9.5 ± 0.2mM), forming compound 64 with a 3-nitrophenyl
group as B-ring, reduced the inhibitory activity considerably
(data not shown). The inversion of the rings of compound 10
(IC50420 mM), resulting in compound 24 (IC50¼ 19.5 ± 1.5mM)
with a 3-nitrophenyl group as B-ring, did not change the activity.
These data allow us to suggest that the 3-nitrophenyl group is well
tolerated at the A-ring, and in the B-ring reduces the inhibitory
activity.
When the 3,4-methylenedioxyphenyl group is the A-ring,
compounds with a 3-nitrophenyl group (34, IC50¼ 11.2 ± 0.3mM)
or a substituted furan (43, IC50¼ 14.8 ± 1.4 mM) as B-ring
showed decreased inhibition of FP-2. When the B-ring was
replaced by a 2,4,5-trimethoxyphenyl group, the inhibitory
activity was further reduced (39, IC50420 mM). Still, compounds
with the 3,4,5-trimethoxyphenyl group as A-ring showed slight
inhibition of FP-2 (72 and 76, both with IC50420 mM), even when
the B-ring is a substituted furan (72) as that present in compound
34 (IC50¼ 11.2 ± 0.3mM). Compounds with chlorine atoms at the
B-ring also showed low inhibitory activity when the A-ring was a
2,4,6-trimethoxyphenyl group (79, IC50420 mM) or a 2-naphthyl
group (23, IC50420 mM).
Determination of the mechanism of FP-2 inhibition by
selected compounds
The three most active compounds, the (E)-chalcones 48, 54 and
66, were used in kinetic analyses for elucidation of the mechanism
of inhibition of FP-2, using different concentrations of Z-FR-
AMC as substrate. Three different concentrations of each inhibitor
were used to calculate the Ki values (10, 20 and 40 mM for
compounds 48 and 54, and 5, 10 and 20mM for compound 66).
Interestingly, the Lineweaver–Burk double-reciprocal plots for
these three compounds (Figure 2) displayed three different kinetic
behaviors.
In the plot of compound 66 (Figure 2), all lines converged at
the x-axis (–1/KMapp), whereas the y-axis intercepts (1/Vmax app)
varied as a function of the inhibitor concentration. The constant
value of KMapp and the decreased values of Vmax proportional to
increasing inhibitor concentrations indicated that this compound
is a non-competitive inhibitor (a¼ 1), with a Ki value of
7.0 ± 2.2mM.
In the plot of compound 54 (Figure 2), all lines converged at
the y-axis (1/Vmax), so Vmax remained constant. The slope
(–KMapp/Vmax) and x-axis intercepts (–1/KMapp) varied with
inhibitor concentration, and the Kmapp values increased with
increasing inhibitor concentrations. These observations are con-
sistent with a competitive mechanism, where the inhibitor
competes with the substrate for binding to the free enzyme
active site. The Ki value determined for compound 54 was
12.0 ± 1.8 mM.
Figure 3. Peptide mass fingerprint of falcipain-2 with a coverage of 73%. Inset: peak m/z 2263.324 corresponds to the peptide-containing the catalytic
Cys42. The spectrum represents a sum of 4000 lasers shots subtracted from the baseline.
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In the plot of compound 48 (Figure 2), the lines converged
below the x-axis. Vmax app and KMapp decreased as a function of
inhibitor concentration, but to different degrees. This mechanism
is recognized as non-competitive (a51). The Ki value determined
for compound 48 was 44.9 ± 5.95 mM.
Interaction of compounds 48, 54 and 66 with FP-2
analyzed by mass spectrometry
In order to investigate the mechanisms of FP-2 inhibition
observed in the FP-2 kinetic experiments, further analysis of the
interaction between FP-2 and compounds 48, 54 and 66 was done
by MALDI-TOF/TOF mass spectrometry and trypsin protection
assays. The peptide mass fingerprint (PMF) of FP-2 in the
presence of the selected inhibitors at different concentrations
was compared to the PMF without inhibitors, as well as in the
presence of 50 mM substrate.
About 73% of the FP-2 primary structure was covered in
the PMF (Figure S1, Supplementary information). Figure 3
shows a series of ions that correspond to peptides from FP-2
cleaved by trypsin. The inset indicates the peptide 38-
NCGSCWAFSSIGSVESQYAIR-58 (m/z 2263.324), which con-
tains the catalytic Cys42. This peptide covers a large part of the
catalytic pocket (Figure S2, Supplementary information).
The PMF of FP-2 in the presence of the substrate Z-FR-AMC
was used as a control (Figure S3, Supplementary information). In
the presence of the substrate, the peak m/z¼ 2263.324, which
corresponds to the peptide-containing catalytic Cys42, was not
found. This might be explained by the substrate occupying the
catalytic pocket and, therefore protecting it from trypsin digestion.
Spectra of all four replicates showed similar profiles.
We analyzed the PMF spectra of FP-2 in the presence of the
most active inhibitors at the same experimental conditions
(Figure 4). Interestingly, the best inhibitor 66 (IC50¼ 4.94 mM),
which in the kinetics evaluations showed a non-competitive
pattern (Figure 2), failed to protect the catalytic pocket, as seen by
the presence of the peptide-containing Cys42 (m/z 2263.376) in
the spectrum (Figure 4, panel B). Most likely inhibitor 66
interacts with another region of the FP-2 structure, consistent with
its demonstrated non-competitive mechanism of inhibition.
The PMF spectrum of 54 (IC50¼ 9.47 mM) (Figure 4, panel C)
was very similar to that of FP-2 in the presence of the substrate
Figure 5. Peptide mass fingerprint of falcipain-2. The peak corresponding to the peptide 204-NSWGQQWGER-213 is labeled (m/z 1247.719, arrows).
The panels show falcipain-2 in the absence of the inhibitors, in the presence of the non-competitive inhibitor 66, and in the presence of the competitive
inhibitor 54. The spectra represents a sum of 4000 lasers shots subtracted from the baseline. Stars represent the peaks m/z 1928.771 and m/z 2056.878,
which are not affected by inhibitor 66.
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Z-FR-AMC (Figure S3, Supplementary information). The pep-
tide-containing Cys42 was absent, indicating that this inhibitor
might interact with the catalytic pocket, consistent with its
demonstrated competitive mechanism of inhibition (Figure 2).
Inhibitor 48 (IC50¼ 8.45 mM) exhibited a mixed-type inhib-
ition in the kinetics experiments (Figure 2). Its PMF spectra
(Figure 4, panel D) displayed a similar profile to that of
compound 54 (Figure 4, panel C).
We also analyzed other peaks found in the PMF of inhibitors
54 and 66, compared with the control (PMF of FP-2; Figure 3).
Figure 5 shows that peaks at m/z 1928.771 and 2056.878 were
unaltered in the presence of the selected inhibitors. However, the
peak which correspond to the peptide 204-NSWGQQWGER-213
(1247.719 m/z) decreased proportionally with increasing concen-
tration of inhibitor 66, but it was not affected even with the
highest concentrations of inhibitor 54 (300 mM) (Figure 5, lower
panel). This peptide is the first indication of a possible site of
interaction for the inhibitor 66 with FP-2. This region is relatively
far from both the catalytic site and the hemoglobin binding site
(Figure S4, Supplementary information). Moreover, this peptide
contains two tryptophan residues (206 and 210), which may be
used to get insights about FP-2 tertiary structure, for example, by
fluorescence analysis.
Analyses of compounds 48, 54 and 66 by fluorescence
spectroscopy
FP-2 has four tryptophan residues, two of them, apart from each
other (23 and 43) and the other two, (206 and 210) structurally
close. Using tryptophan intrinsic fluorescence analyses, we
evaluated the effect of the selected inhibitors in the tryptophan
microenvironment (Figure 6). All three inhibitors (48, 54 and 66)
decreased tryptophan fluorescence. However, only the non-
competitive inhibitor 66 induced a bathochromic shift of 11 nm
in the tryptophan maximum emission. This shift may represent a
disruption in the tryptophan microenvironment and possibly an
overall conformational change. This data indicate that the most
active inhibitor 66, acting via a non-competitive inhibition
mechanism may interact with a potential allosteric site, which
might be represented by the surroundings of peptide 1247.719 m/z
(Figures 5 and S4). This interaction most likely leads to a
conformational change in FP-2, resulting in the loss of activity.
Conclusions
In this work, we used both structural biology tools and mass
spectrometry to propose inhibition mechanisms of new com-
pounds targeting FP-2. The best three inhibitors were (E)-
chalcones, and presented good IC50 values (4.9–8.5mM), and
different kinetic mechanisms for FP-2 inhibition: competitive
(compound 54), non-competitive with a¼ 1 (compound 66) and
non-competitive with a51 (compound 48). Using mass
spectrometry, we were able to depict a potential allosteric site
where compound 66 binds, located between the catalytic site, and
the hemoglobin binding arm in FP-2. Fluorescence data also
revealed that compound 66 was responsible for modifications in a
particular tryptophan microenvironment leading to a conform-
ational change, which seems consistent with an allosteric inhibitor
interaction. We used a combined enzyme kinetic analysis,
fluorescence spectroscopy and mass spectrometry to determine
inhibition mechanisms for novel FP-2 inhibitors. The (E)-
chalcones 66, 54 and 48, containing a new chemical scaffold for
FP-2 inhibition, are attractive lead compounds for further
optimization.
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25. Osório TM, Delle Monache F, Chiaradia LD, et al. Antibacterial
activity of chalcones, hydrazones and oxadiazoles against methicil-
lin-resistant Staphylococcus aureus. Bioorg Med Chem Lett 2012;
22:225–30.
26. Mascarello A, Nunes RJ, Yunes RA, et al. Compostos acil-
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